This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Europe's premier partnering event
Save the date for next yearNovember 3–5, 2025 | Vienna, Austria

Duane Schulthess
CEO at Vital Transformation
Speaker

Profile

Duane Schulthess is the CEO of Vital Transformation, a consultancy focused on quantifying and defining innovation and change in the health-care sector. He regularly works with regulators, multi-national corporations, governments, and stakeholder groups, clarifying the impact of health policy changes and technological innovations.

He has been a speaker at many leading international conferences including BIO, the European Health Forum Gastein, DIA, and The Basel Biozentrum. Mr. Schulthess’ 2019 BMJ publication titled “Are CAR-T therapies living up to their hype?” is considered a ground-breaking analysis in the field of real-world evidence, and has been cited in presentations by the European Medicines Agency and EUnetHTA. Duane is also the host and Executive Producer of the Vital Health Podcast, which has been ranked in the top 30 healthcare podcasts by traffic.

Previously, Duane was the EMEA Head of Corporate Development of The Wall Street Journal, and was the Commercial Director of Science|Business. He has a BA Magna Cum Laude from the University of the Pacific where he was also nominated to the Phi Kappa Phi honour society, and an MBA with Distinction from KU Leuven’s Vlerick Management School. From 1988-91, he was a recipient of a Leverhulme Trust Fellowship at the Royal Academy of Music in London where he won several music performance prizes and competitions while also studying economics on an international exchange programme at Regent’s College. He is a senior associate of the UK’s Royal Society of Medicine.

Agenda Sessions

  • “Mamma Mia”: Transatlantic reflections - assessing US policy impacts on the European biopharma ecosystem

    15:45